IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Who is the best donor for a related HLA haplotype-mismatched transplant?
Wang, Yu1; Chang, Ying-Jun1; Xu, Lan-Ping1; Liu, Kai-Yan1; Liu, Dai-Hong1; Zhang, Xiao-Hui1; Chen, Huan1; Han, Wei1; Chen, Yu-Hong1; Wang, Feng-Rong1; Wang, Jing-Zhi1; Chen, Yao1; Yan, Chen-Hua1; Huo, Ming-Rui1; Li, Dan1; Huang, Xiao-Jun1,2
刊名BLOOD
2014-08-07
DOI10.1182/blood-2014-03-563130
124期:6页:843-850
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology
资助者Collaborative Innovation Center of Hematology China ; Key Program of National Natural Science Foundation of China ; Beijing Municipal Science and Technology Commission ; Collaborative Innovation Center of Hematology China ; Key Program of National Natural Science Foundation of China ; Beijing Municipal Science and Technology Commission
研究领域[WOS]Hematology
关键词[WOS]STEM-CELL TRANSPLANTATION ; BONE-MARROW-TRANSPLANTATION ; VERSUS-HOST-DISEASE ; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE ; ACUTE-LEUKEMIA ; SINGLE-CENTER ; RISK-FACTORS ; PHASE-II ; DEPLETION ; OUTCOMES
英文摘要

The best donor for a related donor for a human leukocyte antigen (HLA) haplotype-mismatched transplant for hematological neoplasms is controversial. We studied outcomes in 1210 consecutive transplant recipients treated on a uniform protocol. Younger donors and male donors were associated with less nonrelapse mortality (NRM; hazard ratio [HR] = 0.30; 95% confidence interval [CI] = 0.01-0.39; P = .008 and HR = 0.65; 95% CI = 0.49-0.85; P = .002) and better survival (HR = 0.73; 95% CI = 0.54-0.97; P = .033 and HR = 0.73; 95% CI = 0.59-0.91; P = .005). Father donors were associated with less NRM (HR = 0.65; 95% CI = 0.45-0.95; P = .02), acute graft-versus-host disease (GVHD) (HR = 0.69; 95% CI = 0.55-0.86; P = .001), and better survival (HR = 0.66; 95% CI = 0.50-0.87; P = .003) compared with mother donors. Children donors were associated with less acute GVHD than sibling donors (HR = 0.57; 95% CI = 0.31-0.91; P = .01). Older sister donors were inferior to father donors with regard to NRM (HR = 1.87; 95% CI = 1.10-3.20; P = .02) and survival (HR = 1.59; 95% CI = 1.05-2.40; P = .03). Noninherited maternal antigen-mismatched sibling donors were associated with the lowest incidence of acute GVHD compared with parental donors and noninherited paternal antigen-mismatched sibling donors. Specific HLA disparities were not significantly correlated with transplant outcomes. Our data indicate which HLA haplotype-mismatched related donors are associated with the best transplant outcomes in persons with hematological neoplasms.

语种英语
所属项目编号81230013 ; Z121107002812033 ; Z121107002612035
资助者Collaborative Innovation Center of Hematology China ; Key Program of National Natural Science Foundation of China ; Beijing Municipal Science and Technology Commission ; Collaborative Innovation Center of Hematology China ; Key Program of National Natural Science Foundation of China ; Beijing Municipal Science and Technology Commission
WOS记录号WOS:000342620400011
引用统计
被引频次:76[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62000
专题北京大学第二临床医学院_血液科
作者单位1.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
2.Peking Univ, Inst Hematol, Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Wang, Yu,Chang, Ying-Jun,Xu, Lan-Ping,et al. Who is the best donor for a related HLA haplotype-mismatched transplant?[J]. BLOOD,2014,124(6):843-850.
APA Wang, Yu.,Chang, Ying-Jun.,Xu, Lan-Ping.,Liu, Kai-Yan.,Liu, Dai-Hong.,...&Huang, Xiao-Jun.(2014).Who is the best donor for a related HLA haplotype-mismatched transplant?.BLOOD,124(6),843-850.
MLA Wang, Yu,et al."Who is the best donor for a related HLA haplotype-mismatched transplant?".BLOOD 124.6(2014):843-850.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Yu]的文章
[Chang, Ying-Jun]的文章
[Xu, Lan-Ping]的文章
百度学术
百度学术中相似的文章
[Wang, Yu]的文章
[Chang, Ying-Jun]的文章
[Xu, Lan-Ping]的文章
必应学术
必应学术中相似的文章
[Wang, Yu]的文章
[Chang, Ying-Jun]的文章
[Xu, Lan-Ping]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。